{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["20(1)"],"submitter":["Yokote K"],"funding":["Kowa Company Ltd."],"pubmed_abstract":["Background
Increased risk of cardiovascular events is associated not only with dyslipidemias, but also with abnormalities in glucose metabolism and liver function. This study uses pooled analysis to explore the in-depth effects of pemafibrate, a selective peroxisome proliferator-activated receptor α modulator (SPPARMα) already known to decrease elevated triglycerides, on glucose metabolism and liver function in patients with hypertriglyceridemia.Methods
We performed a post-hoc analysis of six phase 2 and phase 3 Japanese randomized double-blind placebo-controlled trials that examined the effects of daily pemafibrate 0.1 mg, 0.2 mg, and 0.4 mg on glucose metabolism markers and liver function tests (LFTs). Primary endpoints were changes in glucose metabolism markers and LFTs "],"journal":["Cardiovascular diabetology"],"pagination":["96"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8097867"],"repository":["biostudies-literature"],"pubmed_title":["Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials."],"pmcid":["PMC8097867"],"pubmed_authors":["Yokote K","Nojima T","Yamashita S","Araki E","Ishibashi S","Suganami H","Matsushita M","Arai H"],"additional_accession":[]},"is_claimable":false,"name":"Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials.","description":"Background
Increased risk of cardiovascular events is associated not only with dyslipidemias, but also with abnormalities in glucose metabolism and liver function. This study uses pooled analysis to explore the in-depth effects of pemafibrate, a selective peroxisome proliferator-activated receptor α modulator (SPPARMα) already known to decrease elevated triglycerides, on glucose metabolism and liver function in patients with hypertriglyceridemia.Methods
We performed a post-hoc analysis of six phase 2 and phase 3 Japanese randomized double-blind placebo-controlled trials that examined the effects of daily pemafibrate 0.1 mg, 0.2 mg, and 0.4 mg on glucose metabolism markers and liver function tests (LFTs). Primary endpoints were changes in glucose metabolism markers and LFTs ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 May","modification":"2026-05-02T10:49:22.997Z","creation":"2022-02-10T09:43:55.634Z"},"accession":"S-EPMC8097867","cross_references":{"pubmed":["33947390"],"doi":["10.1186/s12933-021-01291-w"]}}